ArticleHuman vaccines & immunotherapeutics2025
Safety of co-administration of COVID-19 and seasonal influenza vaccines in individuals with autoimmune diseases from the Canadian National Vaccine Safety Network.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The future of vaccination: Innovations emerging from the COVID-19 pandemic.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Canadian National Vaccine Safety Network conducted active safety surveillance for adverse events following COVID-19 and influenza immunizations. This analysis evaluated the association between the administration of mRNA COVID-19 vaccines, influenza vaccines, or co-administration of both, and health events that prevented daily activities, caused work absenteeism, or necessitated medical consultation among individuals with autoimmune diseases. Between September and December 2022, vaccinated and unvaccinated participants from seven provinces and territories self-reported health events within 7 days post-vaccination or over a 7-day period for unvaccinated individuals. This analysis focused on individuals self-reporting autoimmune diseases. Surveys were completed by 6,506 individuals: 1,743 received co-administered vaccines, 2,986 received COVID-19 vaccines alone, 491 received influenza vaccines alone, and 1,286 were unvaccinated. Health event rates were 9.5% for co-administration, 9.3% for COVID-19 alone, 5.9% for influenza alone, and 6.1% for unvaccinated controls. Compared to unvaccinated individuals, the risk of health events was higher for COVID-19 and influenza co-administration [adjusted relative risk (aRR): 1.89, 95% confidence interval (95% CI) 1.41-2.52], and COVID-19 alone [aRR: 1.86, 95% CI, 1.40-2.47], but not for influenza alone (aRR: 1.16, 95% CI, 0.76-1.78). No significant change in emergency department visits or hospitalizations was observed in any vaccine group compared to unvaccinated controls. In individuals with autoimmune diseases, mRNA COVID-19 vaccination increases mild to moderate health events compared to unvaccinated individuals. However, the rate of these events was similar when COVID-19 vaccines were administered alone or concomitantly with influenza vaccines, indicating no additional risk associated with co-administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.